Patricia Van Arnum was executive editor of Pharmaceutical Technology.
The international Society of Chemical Manufacturers and Affiliates (SOCMA) has outlined its legislative priorities for 2010 for the second session of 111th Congress, plans for its national grassroots program — SOCMA Connect — and efforts to launch a voter-registration drive ahead of the November mid-term elections.
The Society of Chemical Manufacturers and Affiliates outlined its legislative priorities for the second session of the 111th Congress.
Zydus Cadila, a pharmaceutical company based in Ahmedabad, Gujarat, India, will begin conducting trials for a H1N1 vaccine.
Buoyed by an uptick in financing from partnering deals, the US biotechnology industry reached a record high in private and public financing in 2009, but caution remains for 2010.
Despite a challenging current economic environment, the five-year outlook for pharmaceutical outsourcing and ingredients supply is fairly healthy.
Grace McNally, in the Office of Compliance at FDA's CDER, discusses the role of QbD and pharmaceutical quality systems as it relates to contract manufacturing.
Growth in emerging markets and across the generic-drug sector shifts the global demand and supply of active pharmaceutical ingredients.
Hospira, a specialty pharmaceutical company, has agreed to acquire Orchid Chemicals' Pharmaceuticals for $400 million.
Eli Lilly has outlined its growth strategy at its annual meeting with the investment community; chief among the company?s goals are plans to launch two new drugs per year beginning in 2013 and a strategy to increase its position in emerging markets.
Eli Lilly outlined its growth strategy at its annual meeting with the investment community last week.
Sanofi-aventis has signed a memorandum of understanding (MoU) with Prominvest, a fully owned subsidiary of the Russian State Corporation Rostekhnologii, confirming its intent to participate in the Pharmpolis Project.
sanofi-aventis (Paris) announced last week that it has signed a memorandum of understanding (MoU)with Prominvest.
Novartis officially inaugurated its large-scale flu cell-culture vaccine and adjuvant manufacturing facility in Holly Springs, North Carolina.
Particularly in a more connected world, individual contributions can make a difference.
Leading experts share insight on polymorphism and crystallization.
Polymorph screening is a critical step in developing an active pharmaceutical ingredient for a pharmaceutical formulation.
Gerry Migliaccio, senior vice-president of network performance for Pfizer Global Manufacturing, offers perspectives on building supply-chain integrity in emerging markets.
The custom manufacturer and fine-chemicals company adds further capabilities in high-potency and viral-product manufacturing and targets synergies in gene editing with its parent company, Sigma-Aldrich.
The US Society for Chemical Manufacturers and Affiliates (SOCMA) has provided an update of its efforts regarding the recently passed US Chemical and Water Security Act of 2009 (HR 2868), which includes inherently safer technology (IST) requirements that SOCMA opposes.
The Society for Chemical Manufacturers and Affiliates (SOCMA) provided an update as to its grassroots efforts regarding the recently passed Chemical and Water Security Act of 2009 (HR 2868).
Following its $68-billion acquisition of Wyeth, Pfizer has unveiled detailed plans for its global R&D network, which includes consolidation of its R&D facilities.
Following the its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) Pfizer detailed plans for its global research and development (R&D) network, which includes consolidation of its R&D facilities.
Novartis reported that German regulatory authorities approved its adjuvanted cell culture-based Influenza A (H1N1) 2009 monovalent vaccine, Celtura. The company also said it will acquire a stake in Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical.
The European Medicines Agency, the European Center for Disease Prevention and Control, and the Heads of Medicines Agencies issued a European strategy for H1N1 vaccine benefit–risk monitoring.
Vetter moves ahead with a new development facility in the US and expanded capabilities in Germany.
Leading experts from an upcoming conference on biosimilars by the Drug, Chemical, and Associated Technologies Association share their insights on the manufacturing and regulatory considerations for biosimilars.
Exhibitors announce capacity expansions, service enhancements, and new products at CPhI Worldwide in Madrid.
Lonza (Switzerland) has announced a series of cost-cutting measures for the next 12¬–18 months.
The FDA has responded to a citizen petition from the Society of Chemical Manufacturers and Affiliates (SOCMA) that highlighted the disparity in inspections of domestic and foreign drug-manufacturing facilities.
The Society of Chemical Manufacturers and Affiliates (SOCMA) reported last week that the US Food and Drug Administration responded to the association's citizen petition relating to the inspection process of foreign drug-manufacturing facilities.
